OBJECTIVES:  One of the main treatment goals of bronchial asthma (BA) is achieving and maintaining disease control. According guidelines the stepwise management is a common approach. Omalizumab (O) is the unique monoclonal antibody for targeted personalized therapy of severe uncontrolled persistent BA in children. At the present time, the efficacy and safety of medical technology must be confirmed by randomized trials. A patient registry can be used as an alternative method. AIM: To analyze the impact of O in achieving asthma control according to the developed data base of clinical cases of children with uncontrolled severe persistent asthma. METHODS: the pediatric patient registry with uncontrolled severe persistent BA included data of 101children (67.33% boys) from 6 y to 17 y 11 mo (average age 13.4 y), receiving O in addition to basic therapy (the duration of therapy from 1 to 81 mo) were analyzed. The control of symptoms was assessed by the questionnaire - Asthma control test (ACT). RESULTS:  All children (101) had a positive dynamics of BA during the therapy with O: the amount of basic therapy has been reduced (before O the average dose in terms of fluticason propionate was 675 ± 278 mcg, after the therapy - 602 ± 290 mcg), the number of exacerbations and the use of quick-relief medications have been reduced, asthma control has been improved (ACT before was 14 ± 4,5 points, after the therapy - 19 ± 3.61 points). There has not been any severe exacerbation requiring emergency admissions. CONCLUSIONS:  Omalizumab is the target medicine for uncontrolled severe persistent asthma in children improving asthma control. The received results indicate the possibility of using the patient registry as a tool for long-term monitoring and comprehensive assessment.